Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes
Amvuttra and Wainua Are Rivals In The Space
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.